Biostatistical And Pharmacoeconomic Measures
Help Questions
NAPLEX › Biostatistical And Pharmacoeconomic Measures
A comparative study of 900 patients (mean age 55 years; 58% female) with asthma compared Add-on Therapy C vs Add-on Therapy D for preventing exacerbations over 1 year. Exacerbation rates were 0.80 vs 0.90 per patient-year (rate ratio 0.89; 95% CI 0.80 to 0.99; p = 0.04). Annual drug costs were $3,200 (C) vs $2,600 (D). How do the confidence intervals affect the interpretation of the study?
Because the CI is close to 1.0, the result is automatically not statistically significant
The CI means 95% of patients will have a personal rate ratio between 0.80 and 0.99
Because the 95% CI is entirely below 1.0, Therapy C shows a statistically significant reduction in exacerbation rate compared with Therapy D
Because the CI is below 1.0, Therapy C must be clinically large enough to justify any cost
Explanation
This question tests confidence intervals in asthma studies. The key parameter is the 95% CI (0.80 to 0.99) for exacerbation rate ratio. Choice A is the best because it is below 1.0, indicating significance. Choice B assumes cost justification; choice C misapplies to individuals; choice D dismisses due to proximity to 1.0. Exclusion of 1.0 confirms reduction. Clinically, assess against costs ($3,200 vs $2,600 annually).
A budget impact model evaluated formulary addition of a new long-acting injectable antipsychotic for schizophrenia in a Medicaid plan with 100,000 members. Eligible patients were 250 (mean age 36 years; 38% female), with 40% uptake. Pharmacy spending increased by $800,000 annually, and psychiatric hospitalizations decreased by 25 per year (average cost $18,000 each). What does the budget impact model suggest for the healthcare system over 1 year?
Net savings of $800,000 because hospitalizations decreased
Net savings of $350,000 because avoided hospitalization costs ($450,000) exceed added pharmacy costs ($800,000)
No budget impact because schizophrenia outcomes cannot be monetized
Net increase of $350,000 because added pharmacy costs ($800,000) exceed avoided hospitalization costs ($450,000)
Explanation
This question examines budget impact for antipsychotic addition. The key parameter is the net increase from $800,000 pharmacy costs exceeding $450,000 avoided hospitalizations. Choice B is the best, accurately yielding $350,000 net increase. Choice A reverses to savings; choice C overstates savings; choice D dismisses modeling validity. Budget impact quantifies fiscal effects. Frameworks should include sensitivity analyses for uptake and cost variables.
A comparative trial randomized 1,100 patients (mean age 65 years; 44% female) with chronic coronary syndrome to Drug W vs placebo for 18 months. Myocardial infarction occurred in 4.8% vs 6.0% (absolute difference −1.2%; 95% CI −2.6% to 0.2%; p = 0.09). Drug W costs $1,200 per year. What does the p-value indicate about the study results?
If there were truly no difference, there is about a 9% probability of observing a difference at least this large by chance; this is not statistically significant at the 0.05 level
The p-value proves Drug W is not clinically useful
The results are statistically significant because p = 0.09 is less than 0.10
There is a 91% probability Drug W prevents myocardial infarction
Explanation
This question tests p-value meaning in coronary syndrome trials. The key parameter is p=0.09 for myocardial infarction difference. Choice B is the best, correctly interpreting under null and noting non-significance at 0.05. Choice A wrongly deems significant at 0.10; choice C misstates as probability of prevention; choice D overinterprets as proving no utility. p=0.09 >0.05 lacks significance. Clinically, evaluate trends with costs ($1,200 per year) for potential value.
A cost-effectiveness analysis compared two smoking cessation strategies in adults (mean age 46 years; 51% female) with COPD: Strategy 1 (varenicline + counseling) vs Strategy 2 (nicotine patch + counseling). Over 1 year, Strategy 1 cost $820 and produced 0.78 QALYs; Strategy 2 cost $620 and produced 0.77 QALYs. Which treatment is most cost-effective at a willingness-to-pay threshold of $50,000 per QALY?
Strategy 2, because it has lower cost and only slightly fewer QALYs, so it is always preferred
Strategy 2, because the incremental cost-effectiveness ratio is $200,000 per QALY
Strategy 1, because any QALY gain makes a therapy automatically cost-saving
Strategy 1, because the incremental cost-effectiveness ratio is $20,000 per QALY and is below $50,000 per QALY
Explanation
This question assesses cost-effectiveness in smoking cessation. The key parameter is the ICER of $20,000 per QALY for Strategy 1 versus 2. Choice B is the best because it falls below $50,000 per QALY. Choice A ignores ICER; choice C miscalculates ICER; choice D assumes automatic cost-saving. The ICER supports added value. Decision frameworks prioritize strategies with ICERs under thresholds for public health interventions.
A meta-analysis pooled 8 randomized trials (total n = 6,200; mean age 66 years; 41% female) comparing SGLT2 inhibitor therapy vs placebo in patients with heart failure with reduced ejection fraction, including those with and without diabetes. The pooled effect on heart failure hospitalization was relative risk 0.78 (95% CI 0.70 to 0.86; p < 0.001). A payer analysis estimated that avoided hospitalizations would save $1,200 per patient-year, while drug acquisition costs were $4,000 per patient-year. What is the primary conclusion from the meta-analysis?
SGLT2 inhibitors have no effect because the relative risk is close to 1.0
SGLT2 inhibitors significantly reduce heart failure hospitalizations compared with placebo
SGLT2 inhibitors increase hospitalizations because p < 0.001 indicates harm
The results are not statistically significant because the confidence interval includes 0
Explanation
This question tests the interpretation of meta-analysis results in heart failure therapy. The key parameter is the pooled relative risk of 0.78 (95% CI 0.70 to 0.86; p < 0.001) for heart failure hospitalizations. Choice A is the best conclusion because the relative risk below 1.0 and confidence interval excluding 1.0 indicate a significant reduction. Choice B is incorrect as the relative risk is not close to 1.0; choice C misinterprets p < 0.001 as harm; choice D wrongly states the interval includes 0, but for relative risk, significance is based on excluding 1.0. A p-value less than 0.001 strongly supports the treatment effect. Clinically, weigh efficacy against costs like $4,000 per patient-year when considering adoption.
A meta-analysis pooled 6 trials (n = 4,100; mean age 50 years; 64% female) comparing an SSRI vs placebo for generalized anxiety disorder. The pooled response odds ratio was 1.40 (95% CI 1.15 to 1.70; p = 0.001). What is the primary conclusion from the meta-analysis?
The result is not statistically significant because p = 0.001 is greater than 0.0001
SSRIs significantly improve response compared with placebo
SSRIs worsen anxiety because the odds ratio is greater than 1.0
SSRIs do not improve response because the confidence interval includes 1.0
Explanation
This question evaluates meta-analysis on SSRIs for anxiety. The key parameter is the odds ratio of 1.40 (95% CI 1.15 to 1.70; p=0.001). Choice A is the best because the CI excludes 1.0, indicating significance. Choice B notes inclusion of 1.0 incorrectly; choice C misinterprets as worsening; choice D dismisses significance. Exclusion of 1.0 supports efficacy. Clinically, integrate with side effects for treatment decisions.
A meta-analysis pooled 10 studies (n = 9,800; mean age 56 years; 50% female) evaluating pharmacist-led medication therapy management (MTM) vs usual care in patients with uncontrolled hypertension. The pooled mean systolic blood pressure reduction was −4.5 mmHg (95% CI −6.0 to −3.0; p < 0.001). MTM cost $120 per patient-year to deliver and reduced cardiovascular-related hospitalizations by 0.01 per patient-year (estimated $15,000 per hospitalization). What is the primary conclusion from the meta-analysis?
MTM is not effective because the reduction is only 4.5 mmHg, which cannot be statistically significant
MTM significantly lowers systolic blood pressure compared with usual care
MTM does not lower blood pressure because the confidence interval includes 0
MTM increases blood pressure because p < 0.001 indicates harm
Explanation
This question evaluates meta-analysis on MTM in hypertension. The key parameter is the mean reduction of −4.5 mmHg (95% CI −6.0 to −3.0; p<0.001). Choice A is the best because the CI excludes 0, indicating significance. Choice B notes inclusion of 0 incorrectly; choice C misinterprets p as harm; choice D dismisses clinical relevance. Exclusion of 0 confirms effect. Clinically, weigh delivery costs ($120 per patient-year) against hospitalization reductions.
A cost-effectiveness analysis compared a new oral multiple sclerosis therapy (Drug U) vs an injectable (Drug V) in 2,000 adults (mean age 39 years; 72% female). Over 5 years, Drug U yielded 3.90 QALYs at $310,000, while Drug V yielded 3.80 QALYs at $290,000. Which treatment is most cost-effective at a willingness-to-pay threshold of $150,000 per QALY?
Drug V, because it has a lower total cost and therefore must be the most cost-effective
Drug U, because its incremental cost-effectiveness ratio is $200,000 per QALY and is below $150,000 per QALY
Drug V, because Drug U’s incremental cost-effectiveness ratio is $200,000 per QALY, which exceeds $150,000 per QALY
Drug U, because having higher QALYs always justifies higher costs
Explanation
This question assesses cost-effectiveness in multiple sclerosis therapy. The key parameter is the ICER of $200,000 per QALY for Drug U versus V. Choice C is the best because the ICER exceeds $150,000 per QALY, favoring V. Choice A prioritizes cost without QALYs; choice B misstates the ICER as below threshold; choice D ignores ICER evaluation. The ICER highlights poor value for small QALY gain. Use thresholds to balance efficacy and affordability in chronic disease management.
A cost-effectiveness study compared an oral hepatitis C regimen (Regimen P) vs an older regimen (Regimen Q) in 1,200 adults (mean age 52 years; 40% female) with compensated cirrhosis. Sustained virologic response was 95% with P vs 90% with Q (p = 0.03). Total treatment cost was $24,000 for P vs $18,000 for Q, and the model estimated lifetime QALYs of 14.6 (P) vs 14.4 (Q). Which treatment is most cost-effective at a willingness-to-pay threshold of $50,000 per QALY?
Regimen P, because its incremental cost-effectiveness ratio is $30,000 per QALY and is below $50,000 per QALY
Regimen P, because a statistically significant p-value always means the therapy is cost-saving
Regimen Q, because it is less expensive and p = 0.03 is not clinically important
Regimen Q, because the incremental cost-effectiveness ratio is $3,000 per QALY
Explanation
This question assesses cost-effectiveness in hepatitis C treatment. The key parameter is the ICER of $30,000 per QALY for Regimen P versus Q. Choice B is the best because the ICER is below the $50,000 per QALY threshold, favoring P. Choice A dismisses statistical significance without ICER context; choice C misattributes the ICER to Q; choice D wrongly links significance to cost-saving. The ICER reflects value from higher sustained virologic response. Use willingness-to-pay thresholds to determine if incremental benefits justify costs in resource-limited settings.
In a comparative effectiveness trial, 420 adults (mean age 62 years; 52% female) with type 2 diabetes and established cardiovascular disease were randomized to Drug A vs Drug B for 24 weeks. The primary outcome (hemoglobin A1c reduction) was −1.1% with Drug A vs −0.9% with Drug B (mean difference −0.2%, 95% CI −0.35 to −0.05; p = 0.01). A cost analysis estimated total 24-week medication costs of $2,400 (Drug A) vs $1,800 (Drug B). What does the p-value indicate about the study results?
Drug A will reduce hemoglobin A1c by 1.1% in 99% of patients
If there were truly no difference between Drug A and Drug B, there is about a 1% probability of observing a difference at least this large due to random chance
There is a 1% chance that Drug A is clinically better than Drug B
The 95% confidence interval means there is a 95% probability the true difference is exactly −0.2%
Explanation
This question tests the interpretation of p-values in clinical trials. The key parameter is the p-value of 0.01 for the mean difference in hemoglobin A1c reduction. Choice B is the best interpretation because it correctly describes the p-value as the probability of observing the data (or more extreme) assuming the null hypothesis of no difference is true. Choice A is incorrect because the p-value does not represent the probability that one drug is clinically better; choice C misinterprets the result as applying to individual patients rather than the study population; choice D wrongly states that the confidence interval gives the probability of the true difference being exactly -0.2%. A p-value less than 0.05 indicates statistical significance, suggesting the observed difference is unlikely due to chance alone. In clinical decision-making, combine p-values with effect sizes and confidence intervals to assess practical importance.